ARTCLINE GmbH

ARTCLINE GmbH develops innovative therapy methods for intensive care medicine based on immune cells. Our current main project is the development of the so-called ARTICE technology for the treatment of bacterial sepsis. ARTCLINE's vision is the development of innovative immune cell-based therapy approaches and to make the technology available to physicians and hospitals worldwide. The safety and effectiveness of the therapy is our top priority. Our extensive cell biological, clinical and industrial experience in the fields of immunology, sepsis diagnostics and therapy help us to realize our vision. Together with scientists and partners, we focus our research activities on the root causes and correlations of sepsis. For many years, the founders and the team of ARTCLINE GmbH have been successfully involved in the transfer of medical inventions from university research to industrial application. We have an extensive network and long standing experience in the development and successful marketing of medical devices and drugs.